Word

DXT

Status

Dead

Status Code

606

Status Date

Monday, September 5, 2022

Serial Number

90042373

Mark Type

4000

Filing Date

Wednesday, July 8, 2020

Published for Opposition

Tuesday, December 15, 2020

Abandoned Date

Monday, September 5, 2022

Trademark Owner History

DOMPÉ FARMACEUTICI SPA - Owner At Publication

Classifications

9 downloadable computer software for use in identifying new drugs; downloadable computer software for use by doctors and other medical professionals in capturing, tracking, reporting, analyzing health data for use in making informed medical decisions; downloadable virtual reality software for medical teaching; downloadable virtual reality software for medical screening; downloadable computer software platforms for use in database management in the field of medicine; downloadable computer application software for mobile phones, namely, software for use in identifying new drugs; downloadable computer software using artificial intelligence for use in identifying new drugs; none of the foregoing for use with blood-related cell processing devices, blood-related medical and laboratory devices, blood-related software and technology, or blood-related medical device and data management systems

5 Pharmaceutical preparation for the treatment of respiratory diseases; pharmaceutical preparation for the treatment of bone diseases; analgesic and muscle relaxant pharmaceutical preparations; antibacterial pharmaceuticals; anti-epileptic pharmaceutical preparations; balms for pharmaceutical purposes; capsules sold empty for pharmaceuticals; cardiovascular pharmaceutical preparations; ocular pharmaceuticals; pharmaceutical products for ophthalmological use; pharmaceutical preparations for ocular or intraocular surgery; pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparations for the prevention and treatment of rare ocular disorders or diseases; pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases; pharmaceutical antitussive cold preparations; pharmaceutical preparations for use in chemotherapy; pharmaceutical products for the treatment of viral and infectious diseases; pharmaceutical products for the treatment of cancer; pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in the treatment of rare tissue and organ transplantation-related diseases and conditions; pharmaceutical preparations for use in tissue and organ transplantation; pharmaceutical preparations, namely, anticoagulants; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for peripheral nervous system; pharmaceutical preparations for the treatment of rare diabetes-related conditions; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for the treatment of bacteria-based diseases; pharmaceutical preparations, namely, antiviral preparations, antibiotics, antifungal preparations and vaccines; pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations, namely, an analgesic for human consumption taken orally; disinfectants for hygiene purposes; none of the foregoing for use with blood-related cell processing devices, blood-related medical and laboratory devices, blood-related software and technology, or blood-related medical device and data management systems for peripheral nervous system; pharmaceutical preparations for the treatment of rare diabetes-related conditions; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for the treatment of bacteria-based diseases; pharmaceutical preparations, namely, antiviral preparations, antibiotics, antifungal preparations and vaccines; pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations, namely, an analgesic for human consumption taken orally; disinfectants for hygiene purposes; none of the foregoing for use with blood-related cell processing devices, blood-related medical and laboratory devices, blood-related software and technology, or blood-related medical device and data management systems

42 software as a service (SAAS) services featuring software using artificial intelligence for use in identifying new drugs; providing a website featuring non-downloadable software using artificial intelligence for use in identifying new drugs; research in the field of artificial intelligence; design and development of computer software in the field of medicine; design and development of virtual reality software for medical screening; design and development of virtual reality software for medical teaching

Trademark Events

Sep 6, 2022

Abandonment Notice E-Mailed - No Use Statement Filed

Sep 5, 2022

Abandonment - No Use Statement Filed

Feb 4, 2022

Notice Of Approval Of Extension Request E-Mailed

Feb 2, 2022

Sou Extension 1 Granted

Feb 2, 2022

Sou Extension 1 Filed

Feb 2, 2022

Teas Extension Received

Aug 3, 2021

Noa E-Mailed - Sou Required From Applicant

Jun 24, 2021

Extension Of Time To Oppose Process - Terminated

Jun 3, 2021

Changes/Corrections After Pub Approval Entered

Jun 2, 2021

Assigned To Petition Staff

May 25, 2021

Teas/Email Correspondence Entered

May 25, 2021

Correspondence Received In Law Office

Mar 29, 2021

Teas Post Publication Amendment Received

Jan 8, 2021

Extension Of Time To Oppose Received

Dec 15, 2020

Official Gazette Publication Confirmation E-Mailed

Dec 15, 2020

Published For Opposition

Nov 25, 2020

Notification Of Notice Of Publication E-Mailed

Nov 9, 2020

Approved For Pub - Principal Register

Nov 7, 2020

Teas/Email Correspondence Entered

Nov 6, 2020

Correspondence Received In Law Office

Nov 6, 2020

Teas Response To Office Action Received

Oct 20, 2020

Notification Of Non-Final Action E-Mailed

Oct 20, 2020

Non-Final Action E-Mailed

Oct 20, 2020

Non-Final Action Written

Oct 16, 2020

Assigned To Examiner

Aug 6, 2020

New Application Office Supplied Data Entered In Tram

Jul 11, 2020

New Application Entered In Tram